Core Viewpoint - Fangsheng Pharmaceutical's stock has shown mixed performance in recent trading, with a year-to-date increase of 13.69% but a recent decline over the past 20 days of 9.11% [2] Group 1: Stock Performance - As of September 18, Fangsheng Pharmaceutical's stock price rose by 2.25% to 11.38 CNY per share, with a trading volume of 1.29 billion CNY and a turnover rate of 2.64%, resulting in a total market capitalization of 4.997 billion CNY [1] - The stock has increased by 2.61% over the last five trading days and by 18.42% over the last 60 days [2] Group 2: Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported operating revenue of 834 million CNY, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million CNY [2] - The company has distributed a total of 689 million CNY in dividends since its A-share listing, with 484 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Fangsheng Pharmaceutical was 33,100, an increase of 0.37% from the previous period, with an average of 13,245 circulating shares per shareholder, a decrease of 0.36% [2] - The top three circulating shareholders include Industrial Bank Medical Health Stock, holding 5.3997 million shares, and Rongtong Health Industry Flexible Allocation Mixed A/B, which increased its holdings by 500,000 shares to 5 million [3]
方盛制药涨2.25%,成交额1.29亿元,主力资金净流出640.30万元